Peramivir + Placebo Comparator
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Influenza
Conditions
Influenza
Trial Timeline
Oct 1, 2010 → Nov 1, 2010
NCT ID
NCT01224795About Peramivir + Placebo Comparator
Peramivir + Placebo Comparator is a phase 3 stage product being developed by BioCryst Pharmaceuticals for Influenza. The current trial status is terminated. This product is registered under clinical trial identifier NCT01224795. Target conditions include Influenza.
What happened to similar drugs?
20 of 20 similar drugs in Influenza were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01224795 | Phase 3 | Terminated |
Competing Products
20 competing products in Influenza
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1010 | Moderna | Phase 1 | 0 |
| mRNA-1273 | Moderna | Phase 1 | 0 |
| mRNA-1010 | Moderna | Phase 2 | 0 |
| mRNA-1083 Composition 1 Dose A Lot A | Moderna | Phase 2 | 0 |
| mRNA-1010 | Moderna | Phase 3 | 0 |
| mRNA-1011.1 | Moderna | Phase 2 | 0 |
| mRNA-1083.1 | Moderna | Phase 2 | 0 |
| mRNA-1010 | Moderna | Phase 3 | 0 |
| mRNA-1083 | Moderna | Phase 3 | 0 |
| mRNA-1073 | Moderna | Phase 2 | 0 |
| VAL-506440 | Moderna | Phase 1 | 0 |
| mRNA-1083 | Moderna | Phase 3 | 0 |
| mRNA-1083 | Moderna | Phase 2 | 0 |
| mRNA-1010 | Moderna | Phase 3 | 0 |
| VAL-339851 | Moderna | Phase 1 | 0 |
| mRNA-1018-H5 | Moderna | Phase 3 | 0 |
| mRNA-1653 | Moderna | Phase 1 | 0 |
| mRNA-1030 | Moderna | Phase 2 | 0 |
| mRNA-1018 for H5N8 | Moderna | Phase 2 | 0 |
| mRNA-1653 | Moderna | Phase 1 | 0 |